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by the National Heart, Lung, and Blood Institute
Esther S. H. Kim, MD, MPH,* Thomas P. Carrigan, MD,† Venu Menon, MD,*
Cleveland, Ohio
Objectives The aim of this study was to describe international enrollment and participation in National Institutes of Health
(NIH)–sponsored cardiovascular randomized controlled trials (RCTs).
Background RCTs provide the evidence base for major societal guidelines and profoundly influence patient care in the United
States. Increased international involvement in clinical trials has been observed, but the rate of international en-
rollment in NIH-sponsored cardiovascular RCTs has not been described.
Methods The NIH registry of clinical trials was searched for phase III or IV cardiovascular RCTs funded by the National
Heart, Lung, and Blood Institute. Studies with outcomes of myocardial infarction, stroke, or death published be-
tween 1997 and 2009 were included. Rates of international enrollment were obtained from published data or
personal communication with corresponding authors.
Results Twenty-four studies met all inclusion criteria. Nineteen trials including 151,682 patients had international partic-
ipation (IP), with median IP of 9.5% (range 0% to 100%). Coronary artery disease trials (11 studies) had nearly
50% international enrollment. High-risk trials and trials testing acute interventions tended to have higher rates
of IP.
Conclusions Cardiovascular RCTs sponsored by the National Heart, Lung, and Blood Institute have substantial rates of inter-
national enrollment, particularly coronary artery disease trials. Given questions of applicability and ethical and
financial considerations, IP in U.S. clinical trials deserves further scrutiny. (J Am Coll Cardiol 2011;58:671–6)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.066As part of its mission as the “steward of medical and
behavior research for the Nation,” the National Institutes of
Health (NIH) strive to provide “leadership and direction to
programs designed to improve the health of the nation by
conducting and supporting research in the causes, diagnosis,
prevention, and cure of human diseases” (1). Subject to
intense competition and peer review, NIH-supported car-
diovascular (CV) randomized controlled trials (RCTs) rep-
resent the pinnacle of clinical research and seek to answer
critical mechanistic and strategic questions pertinent to the
practice of clinical cardiology in the United States. The
results of these studies profoundly influence patient care
both in the United States and worldwide and universally
result in Class 1 recommendations in the American College
From the *Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
Ohio; and the †Department of Cardiovascular Medicine, University Hospitals Case
Medical Center, Cleveland, Ohio. Dr. Kim is a consultant for Philips Ultrasound and
a recipient of an American College of Cardiology Foundation/GE Career Develop-
ment Award recipient (GE provides contrast media for granted study). All other
authors have reported that they have no relationships to disclose.Manuscript received November 22, 2010; revised manuscript received January 20,
2011, accepted January 26, 2011.of Cardiology and American Heart Association treatment
guidelines. These trials need to be of sufficient sample size
to adequately test new developments in the treatment of CV
disease, and often, insufficient enrollment of U.S. patients
leads to the enrollment of international patients. Our
observation of high rates of international enrollment in
recent landmark, NIH-sponsored CV trials led us to explore
the overall rates of international enrollment in these studies.
See page 677
Methods
This study is an analogue analysis of our prior research,
which investigated the participation of women in NIH-
sponsored trials (2). For that study, we searched the NIH
registry of clinical trials for phase III or IV RCTs under the
category of CV diseases funded by the National Heart,
Lung, and Blood Institute (NHLBI). Studies with primary
outcomes of myocardial infarction, stroke, or death pub-
lished between 1997 and 2006 were included. We updated
this search for the present analysis and included all eligible
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cember 1, 2009. From the primary
reports, supplementary methods
reports, and personal communica-
tions with corresponding authors,
we obtained the total number of
patients randomized, the total
number of patients recruited from
outside of the United States, and the
sites of international recruitment.
The median proportion of in-
ternational participation (IP) per
category and the total number of
international patients enrolled
per category divided by the total
number of randomized patients in
that category ( n international)/
( n randomized) are reported. Trials were then categorized
according to the CV disease processes studied: coronary
artery disease (CAD), electrophysiologic disease, congestive
heart failure, hypertension, or primary prevention of CV
disease. Trials were further categorized by level of invasive-
ness of the intervention being tested (invasive or noninva-
sive) and the level of acuity of the patients when recruitment
for the trial occurred. Trials were considered acute if the
intervention occurred during the acute phase of illness, such
as myocardial infarction, decompensated heart failure, acute
arrhythmia, or surgery.
Abbreviations
and Acronyms
CAD  coronary artery
disease
CV  cardiovascular
IP  international
participation
NHLBI  National Heart,
Lung, and Blood Institute
NIH  National Institutes
of Health
OAT  Occluded Artery
Trial
RCT  randomized
controlled trial
List of Included StudiesTable 1 List of Included Studies
Study Acronym Study Title (Ref.
ACCORD Action to Control Cardiovascular Risk in Diabetes (18)
ACES Azithromycin in Coronary Events Study (17)
AFFIRM Atrial Fibrillation Follow-Up Investigation of Rhythm Manag
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent
BARI 2D Bypass Angioplasty Revascularization Investigation 2 Diabe
BEST Beta-Blocker Evaluation in Survival Trial (22)
CABG Patch Coronary Artery Bypass Graft Patch Trial (23)
ENRICHD Enhancing Recovery in Coronary Heart Disease (24)
ESCAPE Evaluation Study of Congestive Heart Failure and Pulmona
FAAT Fatty Acid Antiarrhythmia Trial (26)
HATS HDL-Atherosclerosis Treatment Study (27)
MAGIC Magnesium in Coronaries (28)
M-HART Montreal Heart Attack Readjustment Trial (29)
MOST Mode Selection Trial in Sinus Node Dysfunction (30)
MUSTT Multicenter Unsustained Tachycardia Trial (31)
OAT Occluded Artery Trial (32)
PEACE Prevention of Events With Angiotensin-Converting Enzyme
— Postmenopausal Hormone Therapy in Unstable Angina (34
REMATCH Randomized Evaluation of Mechanical Assistance for the T
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial (36)
SHOCK Should We Emergently Revascularize Occluded Coronaries
STICH Surgical Treatment for Ischemic Heart Failure (hypothesis 2
WHI Women’s Health Initiative (39)
WHS Women’s Health Study (40)HDL  high-density lipoprotein; JACC  Journal of the American College of Cardiology; NEJM  New EngResults
In our original search strategy, there were 11,918 clinical
trials sponsored by the NIH, 1,488 of which were funded by
the NHLBI. Of the 982 studied CV disease, 141 were
completed phase III or IV RCTs in adults, of which 53 had
primary outcomes of myocardial infarction, stroke, or death.
Of the 53, 26 were not published within the pre-specified
time frame, and 5 had no published data. Since our original
search, completed on November 16, 2007, 3 more trials
were published meeting all inclusion criteria, resulting in 25
trials overall. Complete information was available for 24 of
them (Table 1).
There were 11 CAD trials, 3 congestive heart failure
trials, 6 electrophysiologic disease trials, 1 hypertension
trial, and 3 primary prevention trials. Nineteen trials had IP
(Table 2), and the overall median IP was 9.5% (range 0% to
100%) (Table 3). Fifteen percent of all enrollees in NHLBI-
sponsored CV RCTs are from outside the U.S. CAD trials
had the highest proportion of IP, and individual trials are
illustrated in Figure 1. IP in trials of other categories of CV
disease was much smaller (0.3% to 15.8%), but there was a
trend toward increased IP in higher risk trials (physically
invasive interventions) and trials performed during the acute
phase of illness, although the statistical significance of these
findings were not explored. Canada was the most commonly
listed international site and enrolled patients for 16 of 24
trials (Table 2).
Journal Publication Year
NEJM 2008
NEJM 2005
(19) NEJM 2002
Attack Trial (20) JAMA 2000
1) NEJM 2009
NEJM 2001
NEJM 1997
JAMA 2003
ry Catheterization Effectiveness (25) JAMA 2005
Circulation 2005
NEJM 2001
Lancet 2002
Lancet 1997
NEJM 2002
NEJM 1999
NEJM 2006
r Therapy (33) NEJM 2004
JACC 2002
nt of Congestive Heart Failure (35) NEJM 2001
NEJM 2005
rdiogenic Shock (37) NEJM 1999
NEJM 2009
JAMA 2002
NEJM 2005#)
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)
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Although there is heterogeneity in international enrollment
in NHLBI-sponsored CV RCTs, enrollment outside the
United States in these federally funded trials appears sub-
stantial, especially for those trials studying atherosclerotic
CAD. Nine of the 11 CAD trials had IP, and 50% of all
patients enrolled in NIH-sponsored CAD trials are from
outside the United States. In the most recent STICH
(Surgical Treatment for Ischemic Heart Failure) trial, 80%
of subjects were recruited internationally. In light of these
findings, the reasons and consequences of increasing IP in
CV trials deserve exploration.
IP in federally funded clinical trials has a number of
potential benefits. Despite a decline in age-adjusted CV
morbidity in developed nations, the overall global burden of
CV disease continues to rise exponentially, particularly in
developing countries (3,4). By participating in NIH trials,
nations that do not have the robust research infrastructure of
the United States have an opportunity to participate in
International Participation in NIH-Sponsored Cardiovascular RandomTable 2 International Participation in NIH-Sponsored Cardiovas
Trial (Ref. #) Number Randomized Number International
CAD
ACES (17) 4,012 0
BARI 2D (21,41) 2,368 869
ENRICHD (24) 2,481 0
HATS (27) 160 26
MAGIC (28,42) 6,213 5,933
M-HART (29) 1,376 1,376
OAT (32) 2,166 1,678
PEACE (33) 8,290 3,482
PHT (34)† 293 21
SHOCK (32) 302 127
STICH (38) 1,000 800
CHF
BEST (22)‡ 2,708 63
ESCAPE (25)§ 433 10
REMATCH (35) 129 0
EPS
AFFIRM (19,43) 4,060 660
CABG Patch (23) 900 34
FAAT (26) 402 0
MOST (30)¶ 2,010 111
MUSTT (31)# 704 66
SCD-HeFT (36)** 2,521 244
HTN
ALLHAT (20) 42,419 6,722
PRE
ACCORD (18,46) 10,251 1,058
WHI (39,47) 16,608 0
WHS (40,48) 39,876 120
*Patients recruited from Puerto Rico were included in the U.S. count in this trial. †S. P. Schulma
Stevenson, personal communication, August 2007. J. T. Bigger, personal communication, August
2007. **G. H. Brady, personal communication, August 2007.
CAD  coronary artery disease; CHF  congestive heart failure; EPS  electrophysiologic; HTN
revention of cardiovascular disease; other abbreviations as in Table 1.rigorously conducted research protocols. Ideally, clinicaltrialists in these nations would be exposed to the scrutiny,
operational rigor, and ethical considerations that govern
these well-coordinated studies, creating an international
pool of trialists well versed in the ethical conduct of
research. Trial participation in these environments also
enables research subjects to obtain access to cutting-edge
treatment and interventions in areas of clinical equipoise.
Smaller nations that do not have the overall population to
perform well-powered clinical trials are able to contribute to
the evidence gathering process in these studies, giving them
a gauge of the effectiveness of the tested interventions in
their individual health care environments. Increasing inter-
national enrollment may also facilitate the timely comple-
tion of sample size goals for large studies, thus leading to
statistically definitive trial results.
Increasing IP in clinical trials may also be perceived
negatively. The ethical and transparency concerns regarding
the conduct of clinical trials in developing countries have
been recently highlighted (5,6). Increased IP in NIH
Clinical TrialsRandomized Clinical Trials
IP International Sites
0 —
6.7 Canada, Brazil, Mexico, Czech Republic, Austria
0 —
6.3 Canada
5.5 Australia, Austria, Belgium, Bulgaria, Canada, Chile, Georgia, Hungary,
Israel, the Netherlands, New Zealand, Russia, Venezuela
0.0 Canada
7.5 Canada, Latin America, Australia and New Zealand, Europe, Israel
2.0 Italy, Canada, Puerto Rico*
7.2 Brazil
2.1 Canada, New Zealand, Belgium, Australia, Switzerland, Brazil
0.0 Poland, Canada, Western Europe, other
2.3 Canada
2.3 Canada
0 —
6.3 Canada
3.8 Germany
0 —
5.5 Canada
9.4 Canada
9.7 Canada, New Zealand
5.8 Canada, Puerto Rico, U.S. Virgin Islands (44,45)
0.3 Canada
0 —
0.3 Puerto Rico
nal communication, January 2008. ‡M. Bristow, personal communication, August 2007. §L. W.
K. L. Lee, personal communication, August 2007. #A. E. Buxton, personal communication, August
ertension; IP  international participation; NIH  National Institutes of Health; PRE  primaryizedcular
%
3
1
9
10
7
4
4
8
1
1
1
n, perso
2007. ¶clinical trials may also challenge the generalizability of the
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physician acceptance when applied in the U.S. population.
The treatment effect of an intervention in clinical trials may
be strongly influenced by baseline patient characteristics,
background medical therapy, ascertainment of clinical
events, and the completeness and rigor of clinical follow-up,
all of which show geographic variability. Multinational large
CAD trials have shown significant differences in baseline
characteristics as well as outcomes between U.S. and non-
U.S. populations (7). In the HERO-2 (Hirulog and Early
Reperfusion or Occlusion 2) trial, a significant variation in
30-day mortality was observed that ranged from 6.7% in the
heparin arm of Western countries to 10.3% in Latin
America and 13.7% in Russia and Asia, differences that
persisted despite adjustment for baseline characteristics,
treatment, national health, and economic statistics. In
contrast, rates of reinfarction on heparin were highest in the
Western nations at 5.1%, compared with 2.8% in Eastern
Europe, likely reflecting inadequate enzymatic and electro-
cardiographic surveillance (8). The observed treatment ef-
fect in the PURSUIT (Platelet IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrilin Therapy) trial was
greatest in North America, with no observed benefit for
integrilin in Latin America and Eastern Europe on univar-
iate analysis. The geographical differences in outcome in
this study were largely explained by differences in patient
characteristics but were also significantly influenced by the
definition of nonfatal myocardial infarction (9). In con-
trast to the overall study results, an analysis of PLATO
(Study of Platelet Inhibition and Patient Outcomes)
showed numerically higher rates of clinical outcomes for
all efficacy measures with ticagrelor over clopidogrel,
including myocardial infarction, stroke, all-cause mortal-
ity, and CV death for U.S. participants in the trial (10).
We acknowledge that Canada was the most common
non-U.S. site listed among the trials included in our study.
International Participation by Disease Category,Dis ase Acuity, and Invasiveness of Studied ProcedureTable 3 Inter ational Participation by Disease Category,Disease Acuity, and Invasiveness of Studied Procedure
Variable Median % IP (Range)
% IP ( n International/
 n Randomized)
Type of study
CAD (n  11) 42.0 (0–95.5) 49.9 (14,312/28,661)
CHF (n  3) 2.3 (0–2.3) 2.2 (73/3,270)
EPS (n  6) 7.4 (0–16.2) 10.5 (1,115/10,597)
HTN (n  1) 15.8 15.8 (6,722/42,419)
PRE (n  3) 0.3 (0–10.3) 1.8 (1,178/66,735)
Acuity
Acute (n  10) 23.0 (0–95.5) 65.7 (9,538/14,508)
Chronic (n  14) 7.6 (0–16.3) 10.1 (13,861/137,174)
Risk
High (n  9) 9.7 (0–42.1) 36.4 (3,828/10,523)
Low (n  15) 7.2 (0–100) 13.9 (19,571/141,159)
Overall (n  24) 9.5 15.4 (23,399/151,682)
Abbreviations as in Table 2.Some would argue that Canada is a developed country withsimilar demographic characteristics to the United States, but
previous investigations into the differences in patterns of
care for patients in these 2 countries have shown otherwise.
Canada has a universal health care system and spends less
money per capita for health care expenditures (U.S. $5,293
[11] vs. U.S. $6,700 [12]). In a review of 3 large trials of
acute coronary syndromes that included comparisons be-
tween Canada and the United States (13), Canadian pa-
tients were more likely to be lighter, less likely to have
hypertension or hypercholesterolemia, and less likely to have
undergone coronary revascularization procedures. Further-
more, more Canadian patients had anterior myocardial
infarctions than U.S. patients, and Canadians were more
likely to present with higher Killip class scores. Time from
symptom onset to thrombolytic or percutaneous interven-
tion was also longer in Canadian patients.
Besides study interpretation and acceptance, IP in NIH
trials does raise other concerns. There is a federal mandate
for the equal inclusion of women and minorities in all
clinical trials conducted by the NIH (14). We wonder
whether the high rates of IP in CAD trials are contributing
to lower rates of enrollment of women and minorities in
these trials (2,15,16). The wide heterogeneity in the enroll-
ment of international patients in large CV RCTs does not
appear to be a fleeting trend. The FREEDOM (Future
Revascularization Evaluation in Patients With Diabetes
Mellitus: Optimal Management of Multivessel Disease)
trial recently completed enrollment, and its results are
eagerly awaited by the medical community. U.S. enrollment
in this potentially landmark study is 360 of 1,901 (19%)
(Michael Farkouh, MD, personal communication, Novem-
ber 2010).
Figure 1 International Enrollment in NIH-Sponsored CAD RCTs
Percentage of international patients enrolled in federally funded cardiovascular
randomized controlled trials (RCTs) by journal and year of publication. The
mean enrollment of international patients in a RCT of coronary artery disease
(CAD) sponsored by the National Heart, Lung, and Blood Institute over the past
15 years is 49.9%. JACC  Journal of the American College of Cardiology;
NEJM  New England Journal of Medicine; NIH  National Institutes of Health;
PHT  Postmenopausal Hormone Therapy in Unstable Angina. Study acronyms
as in Table 1.
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cause for concern. In the United States, we are fortunate to
have outstanding medical research institutions, universities
with medical schools, and tertiary hospitals across the length
and breadth of our nation. Access to clinical trial participa-
tion should not be an issue. The lack of U.S. participation is
certainly not due to clinical relevance of the trial being
tested. These trials in CAD supported by the NIH are peer
reviewed and represent vital issues in CV health care
delivery that warrant study and randomization. Why, then,
is an important trial such as STICH able to enroll only 200
patients in a country of 308 million, when Poland, with a
population of 38 million, enrolls 288 subjects? Similarly,
overall U.S. enrollment in OAT (Occluded Artery Trial) is
488 at 83 sites, compared with 450 at 27 sites in Canada.
What is the cause of these low rates of United States
enrollment in these pivotal clinical trials? Is it hesitancy on
the part of U.S. patients to participate in a research question
considered a top priority by experts in the field? Is it a lack
of desire on the part of U.S. physicians to randomize their
patients to answer a clinical question for which a suitable
answer is yet unavailable? Is it failure of medical institutions
to foster an environment that bolsters research activity? Are
these the consequences of current regulatory and compli-
ance issues that have gone overboard to make research
cumbersome?
We acknowledge that patient enrollment in clinical trials
in the U.S. can be a difficult task and that many of the trials
in this study opened recruitment outside the U.S. because of
inadequate enrollment at U.S. sites. We believe that re-
search into the reasons for the underenrollment of U.S.
patients in these critical clinical trials is urgently warranted.
We also suggest that academia and tertiary medical institu-
tions should be more supportive, with every effort made to
recruit U.S. patients into these NIH trials.
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